In fact, mosliciguat selectively vasodilated ventilated parts of the lung, leading to a reduction in desaturation (Becker-Pelster et al. 2022).Therefore, given its mode of action as an sGC activator and its selective application route, mosliciguat could advance NO-GC-based pharmacotherapy; phase 1b studies for pulmonary hypertension, which are currently underway, will provide more information on the future of this compound in pulmonary hypertension (NCT03754660). This evidence concerns the gene SGCB and pulmonary arterial hypertension.